Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Production Efficiency01:01

Production Efficiency

15.3K
Net production efficiency (NPE) is the efficiency at which organisms assimilate energy into biomass for the next trophic level. Due to low metabolic rates and less energy spent on thermoregulatory processes, the NPE of ectotherms (cold-blooded animals) is 10 times higher than endotherms (warm-blooded animals).
15.3K
Response Surface Methodology01:16

Response Surface Methodology

876
Response Surface Methodology (RSM) is a collection of statistical and mathematical techniques used to develop, improve, and optimize processes. It is particularly valuable when many input variables or factors potentially influence a response variable.
The process of RSM involves several key steps:
876
Increasing Function01:18

Increasing Function

507
An increasing function exhibits a rise in output values as input values increase. This behavior is depicted graphically as a curve or line that slopes upward from left to right. Such a function satisfies the condition that if x1 < x2, then f(x1) < f(x2), indicating that the function values grow with increasing inputs. This concept is fundamental in understanding growth trends across various domains, such as population dynamics, financial investments, or resource consumption.The...
507
Bioreactor Controls-III01:22

Bioreactor Controls-III

67
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
67
Regression Toward the Mean01:52

Regression Toward the Mean

6.3K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

420
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
420

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoreactivity vs autoimmunity: characteristics of autoantigen-specific CD4 T-cells in rheumatoid arthritis and health.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025.

Annals of the rheumatic diseases·2026
Same author

Anti-CD52 therapy of rheumatic diseases: Revisited in the era of immune reset.

Autoimmunity reviews·2026
Same author

Immune reset and immune retune: approaching cure?

Nature reviews. Rheumatology·2026
Same author

Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis.

RMD open·2026
Same author

An Empirical Assessment of the Cost of Dichotomization of the Outcome of Clinical Trials.

Statistics in medicine·2026
Same journal

A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials.

Pharmaceutical statistics·2026
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Apr 21, 2026

Making Record-efficiency SnS Solar Cells by Thermal Evaporation and Atomic Layer Deposition
14:01

Making Record-efficiency SnS Solar Cells by Thermal Evaporation and Atomic Layer Deposition

Published on: May 22, 2015

42.2K

R&D productivity rides again?

Dennis Lendrem1, Stephen J Senn, B Clare Lendrem

  • 1Institute of Cellular Medicine, Newcastle University, UK.

Pharmaceutical Statistics
|October 23, 2014
PubMed
Summary
This summary is machine-generated.

A flawed analysis suggests pharmaceutical R&D productivity improved in 2008. Our re-analysis indicates the industry still faces challenges and systemic issues require resolution for true recovery.

Keywords:
R&D costsR&D productivitycostsdevelopmentpharmaceutical industrypharmaceutical innovation crisisstrategy

More Related Videos

Research and Development of High-performance Explosives
10:33

Research and Development of High-performance Explosives

Published on: February 20, 2016

20.9K

Related Experiment Videos

Last Updated: Apr 21, 2026

Making Record-efficiency SnS Solar Cells by Thermal Evaporation and Atomic Layer Deposition
14:01

Making Record-efficiency SnS Solar Cells by Thermal Evaporation and Atomic Layer Deposition

Published on: May 22, 2015

42.2K
Research and Development of High-performance Explosives
10:33

Research and Development of High-performance Explosives

Published on: February 20, 2016

20.9K

Area of Science:

  • Pharmaceutical industry
  • Research and Development (R&D)

Background:

  • Recent analyses suggested a positive turn in pharmaceutical R&D productivity around 2008.
  • These analyses indicated the industry was recovering from previous challenges.

Purpose of the Study:

  • To critically evaluate the methodology and conclusions of a recent R&D productivity analysis.
  • To present an alternative analysis of the same data to reassess the industry's R&D productivity status.

Main Methods:

  • Re-analysis of existing R&D productivity data.
  • Critique of the statistical and interpretative methods used in a prior study.

Main Results:

  • The previous analysis's conclusion of a 'turned corner' in 2008 was found to be flawed.
  • The alternative analysis indicates that pharmaceutical R&D productivity has not yet fully recovered.

Conclusions:

  • The pharmaceutical industry is not yet 'out of the woods' regarding R&D productivity.
  • Systemic issues impacting pharmaceutical R&D productivity are still in the process of being resolved.